PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。针对T淋巴细胞CD 3受体的单克隆抗体（抗CD 3）已被证明是有效的免疫抑制剂，可用于临床情况，如器官移植和糖尿病后类固醇难治性同种异体移植排斥反应。同时，这些单克隆抗体的施用可能因T细胞活化而复杂化，导致细胞因子释放综合征（CRS）。本研究的目的是研究CNTO 311（一种基因工程抗CD 3 IgG单克隆抗体）对CRS的影响。有利的结果将为开发CNTO 311用于临床提供依据。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monoclonal antibodies directed against the CD3 receptor of T lymphocytes (anti-CD3) have been shown to be effective immunosuppressive agents for use in clinical situations such as steroid-refractory allograft rejection following organ transplantation and diabetes. At the same time, administration of these monoclonal antibodies may be complicated by T-cell activation resulting in cytokine release syndrome (CRS). The purpose of this study is to investigate CNTO311, a genetically engineered anti-CD3 IgG monoclonal antibody, with regard to CRS. Favorable results will provide justification to develop CNTO311 for use in the clinical situations.